Shares of Portola Pharmaceuticals more than doubled on news that Boston-based Alexion Pharmaceuticals is acquiring the company and Portola’s blood-disorder assets for $1.41 billion in cash.
https://www.pharmalive.com/wp-content/uploads/2020/05/Alexion-Set-to-Acquire-Portola-Pharmaceuticals-in-1.41-Billion-Deal-BioSpace-5-5-20.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2020-05-05 11:52:552020-05-05 11:52:55Alexion Set to Acquire Portola Pharmaceuticals in $1.41 Billion Deal